Biosight
Innovative cancer therapeutics
Biosight has raised €28M across 2 funding rounds from 4 investors, most recently a Series C round in Nov 2020. Based in Karmiel, Israel; founded 1999; active in Healthtech. Data as of Nov 2026.
Total raised
€28M
€28,106,214
Funding rounds
2
Investors
4
distinct backers
Active since
2016-05
latest 2020-11
Funding by year
EUR raised per yearBiosight — funding by year — interactive chart.
Data table
| Biosight — funding by year | |
|---|---|
| 2016 | €12M |
| 2020 | €16M |
Signals
High confidenceRaise-next likelihood10
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood4
base rate 11% (2+ rounds)
- ▼ Old (27y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-11-03 | Series C | €16M | Israel Biotech Fund | View deal → |
| 2016-05-01 | Growth/Late | €12M | Arkin Holdings,Michael Ilan Management and Investments,Primera Capital | View deal → |
Related news
Similar companies
same sector, similar size- EQUInom€30MIsrael · Healthtech
- CathWorks€26MIsrael · Healthtech
- BreezoMeter€36MIsrael · Healthtech
- RealView Imaging€21MIsrael · Healthtech
- raziel therapeutics€20MIsrael · Healthtech
- Azura Ophthalmics€17MIsrael · Healthtech
Global coverage: FundingData